Response rate according to the induction or maintenance treatment phase
| . | Response to rituximab maintenance . | |||
|---|---|---|---|---|
| . | CR MRD− . | CR MRD+ . | PR . | Failure . |
| Response to R-FCM, N = 64 | ||||
| CR MRD−, n = 35 | 22 | 9 | 0 | 4 |
| CR MRD+, n = 21 | 2 | 15 | 0 | 4 |
| PR, n = 8 | 2 | 2 | 3 | 1 |
| . | Response to rituximab maintenance . | |||
|---|---|---|---|---|
| . | CR MRD− . | CR MRD+ . | PR . | Failure . |
| Response to R-FCM, N = 64 | ||||
| CR MRD−, n = 35 | 22 | 9 | 0 | 4 |
| CR MRD+, n = 21 | 2 | 15 | 0 | 4 |
| PR, n = 8 | 2 | 2 | 3 | 1 |